US2020171121A1PendingUtilityA1
Cationic antimicrobial peptides
Est. expiryApr 15, 2034(~7.7 yrs left)· nominal 20-yr term from priority
Inventors:Charles M. Deber
A61K 38/16A61K 31/7036A61K 38/10A61K 31/407A61K 31/496A61P 31/04
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method for treating an infection comprises administering a peptide in synergistic combination with an antibiotic, wherein the peptide comprises an amino acid sequence with a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2 ; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of from about 7 to about 24 amino acid residues, said sequence having an average hydrophobicity value of at least 0.3 on the Liu-Deber scale.
Claims
exact text as granted — not AI-modified1 - 21 . (canceled)
22 . A composition comprising a synergistic combination of an antibiotic and a peptide comprising an amino acid sequence with a formula selected from the group consisting of:
(a) B n1 -Z; (b) B n1 -Z-B n2 ; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of from about 7 to about 24 amino acid residues, said sequence having an average hydrophobicity value of at least 0.3 on the Liu-Deber scale.
23 . The composition of claim 22 , wherein the peptide is selected from the group consisting of:
(a)
(SEQ ID NO: 19)
KKKKKKXXFXXWXXFXX-NH 2 ;
(b)
(SEQ ID NO: 20)
KKKKKKAXFAXWXAFXA-NH 2 ;
(c)
(SEQ ID NO: 3)
KKKKKKAAFAAWAAFAA-NH 2 ;
(d)
(SEQ ID NO: 4)
KKAFAAAAAFAAWAAFAKKKK-NH 2 ;
(e)
(SEQ ID NO: 5)
RRRAAFAAWAAFAARRR-NH 2 ;
(f)
(SEQ ID NO: 6)
KKAAAAFAAFAAWFAAFAAAAKKKK-NH 2 ;
(g)
(SEQ ID NO: 7)
KKATALVGAASLTAWVGLASAKKKK-NH 2 .
(h)
(SEQ ID NO: 8)
KKAFAAAAAFAAXAAFAKKKK-NH 2 ;
(i)
(SEQ ID NO: 9)
KKKKKAAAFAAXAAFA-NH 2 ;
(j)
(SEQ ID NO: 10)
RRRAAAFAAXAAFARRR-NH 2 ;
(k)
(SEQ ID NO: 11)
KKAAAAFAAFAAXFAAFAAAAKKKK-NH 2 ;
(l)
(SEQ ID NO: 12)
KKATALVGAASLTAXVGLASAKKKK-NH 2 ;
(m)
(SEQ ID NO: 13)
KKKKKKAAAFAAAAAFAAWAAFAAA-NH 2 ;
(n)
(SEQ ID NO: 14)
KKKAAAFAAWAAFAKKK-NH 2 ;
(o)
(SEQ ID NO: 15)
RRRRRRAAFAAWAAFAA-NH 2 ;
(p)
(SEQ ID NO: 18)
KKKKKKAAAAFWAAAAF-NH 2 ;
(q)
(SEQ ID NO: 17)
KKKKKKAAFAAFAAFAA-NH 2 ;
and
(r)
(SEQ ID NO: 18)
KKKKKKAAWAAWAAWAA-NH 2 ;
wherein X is any hydrophobic amino acid of hydropathy value greater than or equal to alanine.
24 . The composition of claim 23 , wherein the peptide is selected from the group consisting of KKKKKKXXFXXWXXFXX-NH 2 , wherein each X is independently A, L, G, or S (SEQ ID NO: 1): KKKKKKAXFAXWXAFXA-NH 2 , wherein each X is independently selected from A or L (SEQ ID NO:2); and KKKKKKAAFAAWAAFAA-NH 2 (SEQ ID NO:3).
25 . The composition of claim 23 , wherein the amino acids in the peptide are D-amino acids, L-amino acids, or a combination thereof.
26 . The composition of claim 23 , wherein the peptide is a stapled peptide.
27 . The composition of claim 26 , wherein the stapled peptide is a helix stapled peptide.
28 . The composition of claim 23 , wherein the antibiotic is selected from the group consisting, of aminoglycosides, fluoroquinolones, carbapenem beta-lactam antibiotics, and combinations thereof.
29 . The composition of claim 28 , wherein the antibiotic is selected from tobramycin, ciprofloxacin, meropenem, and combinations thereof.
30 . The composition of claim 23 , formulated as a toothpaste, mouthwash, topical skin product, contact lens cleaning or storage solution, parenteral or enteral composition, a cleaning solution, or a cleaning wipe.
31 . (canceled)
32 . A composition comprising KKKKKKAAFAAWAAFAA-NH 2 (SEQ ID NO:3) and an antibiotic selected from the group consisting of tobramycin, ciprofloxacin, and meropenem.Join the waitlist — get patent alerts
Track US2020171121A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.